Giorgia Tosoni

Giorgia Tosoni

Auto-generated profile, based on publicly available information

Giorgia Tosoni

Netherlands Institute for Neuroscience, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2023 in Neuron
Verified
Journal Article
Open access
GTGiorgia Tosoni
Giorgia Tosoni
DADilara Ayyildiz
Dilara Ayyildiz
JBJulien Bryois
Julien Bryois
WMWill Macnair
Will Macnair
CFCarlos P. Fitzsimons
Carlos P. Fitzsimons
ESEvgenia Salta
Evgenia Salta

6 February 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
TLThomas Larrieu
Thomas Larrieu
FGFabio Grieco
Fabio Grieco
CCCharline Carron
Charline Carron
MVMarta Vilademunt
Marta Vilademunt
CWCrystal Weber
Crystal Weber
NTNicolas Toni
Nicolas Toni
Anxiety is an aggravating comorbidity of many psychiatric disorders that is often underdiagnosed and undertreated, and little is known on the mechanisms underlying its regulation. Here, we find that serum LPA16:0 abundance increases with trait anxiety in both humans and mice; while high LPA16:0 levels are sufficient to reduce the in vitro proliferation of adult hippocampal neural stem/progenitor cells. In humans, the main LPA receptor LPA1, bears single nucleotide polymorphism variants associated with anxiety. In mice, LPA16:0 decreases hippocampal neurogenesis and stress resilience, whereas LPA1 antagonism or the reduction of platelets, the main source of circulating LPA16:0, increases adult neurogenesis and resilience to acute stress. Conditional knockdown of LPA₁ receptor in neural stem cells is sufficient to enhance cell proliferation in the dentate gyrus. Finally, the inhibition of adult neurogenesis abolishes the beneficial effect of LPA1 antagonism on resilience against both acute and chronic stress. Together, these findings identify circulating LPA16:0 as a biomarker of trait anxiety and LPA16:0-LPA1 signaling as a regulation mechanism of mood-related behavior through the decrease of adult neurogenesis.

10 January 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
GTGiorgia Tosoni
Giorgia Tosoni
DADilara Ayyildiz
Dilara Ayyildiz
APAmber Penning
Amber Penning
SSSarah Snoeck
Sarah Snoeck
ESEstibaliz Santiago-Mujika
Estibaliz Santiago-Mujika
ESEvgenia Salta
Evgenia Salta
The existence and functional significance of immature neurons in the adult human brain, particularly in the context of neurodegenerative disorders, remain controversial. While rodent studies have highlighted active roles for adult-born immature neurons in the hippocampus under both healthy conditions and in Alzheimer’s disease (AD), evidence from the human brain is limited and lacks detailed molecular characterization. To address this gap, we performed single-nucleus RNA sequencing in aged healthy, AD and dementia-resilient human hippocampus to probe immature neuronal signatures and gene expression alterations associated with AD pathology and resilience. Employing a novel experimental and computational pipeline, we identified persistent populations of immature neurons across all donor groups, with transcriptional profiles distinct from both fetal counterparts and adult mature hippocampal neurons. These profiles were associated with ‘juvenile’ cellular functions, suggesting that the presence of these immature neuronal populations per se may actively contribute to maintaining homeostasis within the aged human hippocampus, a role that may be disrupted in AD. In the resilient brain, immature neurons were involved in transcriptional programs and intercellular interactions associated with anti-inflammatory, neurotrophic, neuroprotective, myelinating, anti-apoptotic and anti-amyloidogenic signaling pathways, suggesting active roles for the immature cells in enhancing cognitive resilience in the presence of AD pathology. Our findings reveal novel, putative physiological roles for immature neurons in the healthy and resilient adult human brain, and offer a resource for probing new strategies with potential functional relevance in AD.

15 October 2026 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
CVCinzia Vicidomini
Cinzia Vicidomini
TGTravis D. Goode
Travis D. Goode
RYRuilin Yu
Ruilin Yu
IMIyanah Mehta
Iyanah Mehta
KMKathleen M. McAvoy
Kathleen M. McAvoy
ASAmar Sahay
Amar Sahay
Cognitive reserve theory posits that compensatory mechanisms during aging stave off cognitive decline and lower risk for Alzheimer’s disease. Here, in a screen for hippocampal dentate granule cell (DGC) synapse loss-induced factors in mice, we identified a secreted phospholipase, Pla2g2f, whose expression increases in DGCs during aging and is associated with cognitive resilience in humans. Pla2g2f deletion in DGCs exacerbates aging-associated pathophysiological changes, including synapse loss, inflammatory microglia, reactive astrogliosis, impaired neurogenesis, lipid dysregulation, lipid droplet accumulation and hippocampal-dependent memory loss. Conversely, boosting Pla2g2f in DGCs during aging is sufficient to prevent these pathophysiological alterations in hippocampal–cortical circuits, protect memory and prophylactically modify trajectory of cognitive decline. Mutagenesis of the catalytic site of PLA2G2F prevented lipid droplet mobilization and reduction of reactive gliosis and inflammatory microglia. Neuronal PLA2G2F mediates intercellular signaling to decrease lipid droplet and cholesterol ester load in human induced pluripotent stem cell-derived microglia. Our findings implicate PLA2G2F as a compensatory neuroprotective broadcast signal that maintains lipid homeostasis to counteract aging-associated cognitive decline.

16 June 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
APAmber Penning
Amber Penning
GTGiorgia Tosoni
Giorgia Tosoni
HWHannah Walgrave
Hannah Walgrave
SSSarah Snoeck
Sarah Snoeck
SBSriram Balusu
Sriram Balusu
ESEvgenia Salta
Evgenia Salta
Background: Mapping the mechanistic heterogeneity and multifactorial nature of AD is a key challenge for therapeutic development and the main reason why network biology and multi‐modal therapies begin to attract attention also in AD research. miRNA‐targeted therapeutics are particularly suited for such purposes, as they regulate multiple components of several molecular cascades converging on disease‐relevant patho‐phenotypes. MicroRNA‐132 (miR‐132), a potent neuroimmune regulator, has been identified as the most robustly and significantly downregulated microRNA in the brain of Alzheimer’s Disease (AD) patients and its deficiency has been functionally linked to amyloid deposition, TAU hyperphosphorylation, neuronal cell death and memory decline, in human and rodents. Of note, miR‐132 can explain a higher percentage of the observed variance in histopathological AD phenotypes than APOE e4, a major risk factor for AD, while more recent evidence functionally links miR‐132 to neuroinflammation. These observations suggest that miR‐132‐dependent network‐based gene regulation in human AD brain converges onto biological pathways that can drive disease endophenotypes. Direct miR‐132 infusion in the AD mouse brain can counteract several aspects of pathology and memory deficits, providing a proof‐of‐concept of its therapeutic relevance. Despite the great benefit of the multi‐targeting nature of microRNAs for treating multifactorial diseases such as AD, this approach also entails the risk of on‐ and off‐ target toxicity, highlighting the importance of systematic genome‐wide target validation. While specific miR‐132 targets with direct implications in amyloid and TAU pathologies have been previously identified, the complex multicellular miR‐132 targetome involved in the disease progression of AD remains elusive, and is a crucial requirement for therapeutic targeting.Method: In order to systematically profile the mechanisms underpinning the regulatory effects of miR‐132 in AD, we employed an RNA‐sequencing approach to assess transcriptomic responses to changes in the levels of miR‐132 in AD‐relevant study systems, such as human iPSC‐derived neurons and microglia‐like cells.Result: We identify novel miR‐132 targets with putative neuroimmune functions possibly involved in AD pathophysiology.Conclusion: Our results shed light on the involvement of miR‐132 in AD and further add to the systematic profiling of miR‐132 targetome, a prerequisite for successful translation of miR‐132 supplementation in AD.

25 December 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
GTGiorgia Tosoni
Giorgia Tosoni
APAmber Penning
Amber Penning
DADilara Ayyildiz
Dilara Ayyildiz
SSSarah Snoeck
Sarah Snoeck
SPSuresh Kumar Poovathingal
Suresh Kumar Poovathingal
ESEvgenia Salta
Evgenia Salta
Background: Alzheimer’s disease (AD) is a progressive, irreversible disorder accounting for 50‐70% of all dementia cases. Given the current lack of disease‐modifying therapies, systematic profiling of the cell type‐ and cell state‐specific molecular signatures of resilience and vulnerability to AD may reveal novel therapeutic avenues. Adult hippocampal neurogenesis (AHN) refers to the birth of new neurons in the neurogenic ‘niche’ of a hippocampal subregion, the dentate gyrus (DG). AHN drops sharply in AD, and positively correlates with ante‐mortem cognition. Our work and previous reports show that boosting AHN in AD mice restores AHN‐related memory. Hence, harnessing AHN in human AD brain may provide novel strategies to prevent or counteract dementia. Insights into the molecular and cellular regulatory networks maintaining homeostasis of the human neurogenic microenvironment are currently missing.Method: Here, we employ single‐nucleus RNA sequencing technology in the human AHN niche to profile cell type specific molecular signatures of AHN and their changes during the course of AD pathology and in resilient brains.Result: We developed a novel protocol for precise microdissection of the AHN niche in tissue sections of postmortem human brain, which yields high‐quality input material, enriched for niche‐resident cell populations. We employ in silico ‘dissection’ of cellular populations putatively including neurogenic cell types, and lineage trajectories to identify any (rare) bona fide progenitors.Conclusion: Using previously published and our own datasets, we identify species‐conserved and human‐specific markers that could be used for more reliable identification of adult neurogenic populations and of their transcriptional alterations in AD and resilient brains.